[CH:1]1[N:5]=[C:4]([CH:6]2[CH2:11][CH2:10][CH2:9][N:8]([C:12]3[N:17]=[C:16]([NH2:18])[C:15]([N+:19]([O-])=O)=[CH:14][CH:13]=3)[CH2:7]2)[N:3]2[CH2:22][CH2:23][CH2:24][C:2]=12.O.[Cl-:26].[Ca+2].[Cl-]>C(O)C.[Fe]>[ClH:26].[CH:1]1[N:5]=[C:4]([CH:6]2[CH2:11][CH2:10][CH2:9][N:8]([C:12]3[N:17]=[C:16]([NH2:18])[C:15]([NH2:19])=[CH:14][CH:13]=3)[CH2:7]2)[N:3]2[CH2:22][CH2:23][CH2:24][C:2]=126-(3-(6,7-Dihydro-5H-pyrrolo[1,2-c]imidazol-3-yl)piperidin-1-yl)-3-nitropyridin-2-amine (20 mg, 0.1 mmol) was dissolved in ethanol (0.5 mL) and water (0.1 mL) under nitrogen. Then iron 200 mesh (27 mg, 0.5 mmol) and calcium chloride (3.3 mg, 0.03 mmol) were added and the mixture was heated to 70° C. for 18 h. The reaction mixture was cooled to room temperature followed by filtration through a 0.2 μm nylon syringe filter and rinsing with ethanol (0.5 mL) to afford the title compound. The filtrate was carried on to the next step without further purification. MS (AP+) (M+H) 299.1; LCMS retention time: 0.44 minutes (Method L)
読み込み中…
